Nektar Therapeutics (NKTR)
NASDAQ: NKTR · Real-Time Price · USD
76.43
+0.93 (1.23%)
Aug 12, 2026, 10:04 AM EDT - Market open

Nektar Therapeutics Revenue

Nektar Therapeutics had revenue of $10.86M in the quarter ending March 31, 2026, with 3.83% growth. This brings the company's revenue in the last twelve months to $55.63M, down -36.24% year-over-year. In the year 2025, Nektar Therapeutics had annual revenue of $55.23M, down -43.89%.

Revenue (ttm)
$55.63M
Revenue Growth
-36.24%
P/S Ratio
45.85
Revenue / Employee
$883,063
Employees
63
Market Cap
2.58B

Revenue Chart

Revenue History

Fiscal Year EndRevenueChangeGrowth
Dec 31, 202555.23M-43.20M-43.89%
Dec 31, 202498.43M8.31M9.22%
Dec 31, 202390.12M-1.93M-2.10%
Dec 31, 202292.06M-9.85M-9.67%
Dec 31, 2021101.91M-51.01M-33.36%
Dec 31, 2020152.92M38.30M33.41%
Dec 31, 2019114.62M-1.08B-90.40%
Dec 31, 20181.19B885.61M287.81%
Dec 31, 2017307.71M142.28M86.00%
Dec 31, 2016165.44M-65.35M-28.32%
Dec 31, 2015230.78M30.08M14.99%
Dec 31, 2014200.71M51.79M34.77%
Dec 31, 2013148.92M67.73M83.42%
Dec 31, 201281.19M9.71M13.59%
Dec 31, 201171.48M-87.56M-55.06%
Dec 31, 2010159.04M87.11M121.10%
Dec 31, 200971.93M-18.25M-20.24%
Dec 31, 200890.19M-182.84M-66.97%
Dec 31, 2007273.03M55.31M25.40%
Dec 31, 2006217.72M91.44M72.41%
Dec 31, 2005126.28M--

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Related Stocks

Company NameRevenue
Ultragenyx Pharmaceutical717.00M
Zai Lab449.61M
Precigen85.72M
Viridian Therapeutics71.13M
Nurix Therapeutics36.77M
AtaiBeckley3.49M
Revenue Rankings